Drugs · acquisition-cost intelligence
COSOPT PF
dorzolamide hydrochloride and timolol maleate· ingredient timololBeta blocking agents· DORZOLAMIDE HYDROCHLORIDE 20 mg/mL; TIMOLOL MALEATE 5 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$1.08
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other timolol products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Timolol Maleate | $0.75535 | −$0.32420 |
| timolol maleate | $0.79615 | −$0.28340 |
| COSOPT | $0.92983 | −$0.14980 |
| Timolol maleate | $1.60 | +$0.52100 |
| Brimonidine Tartrate/Timolol Maleate | $2.38 | +$1.30 |
| Timoptic in Ocudose | $5.94 | +$4.86 |
| Timolol GFS | $13.33 | +$12.25 |
| TIMOLOL MALEATE | $13.33 | +$12.25 |
Medicare Part D coverage · CY2026
On 64 plan formularies · typical tier 4
Prior auth 0% · Step therapy 17% · Quantity limit 11% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.